#United States #Itasca #oncology #Lakeside #Huiyu Pharmaceutical

Lakeside and Huiyu Pharmaceutical Form Strategic Alliance

In a significant move aimed at revolutionizing oncology drug distribution, Lakeside Holding Limited, a U.S.-based cross-border supply chain provider, has forged a strategic partnership with Sichuan Huiyu Pharmaceutical Co., Ltd. This collaboration is poised to enhance the reach of oncological and immunotherapy treatments across both domestic and global markets.

Huiyu Pharmaceutical, currently listed on the Shanghai Stock Exchange, is widely recognized for its innovations in oncology and immune-related therapies. With a strong commitment to addressing critical healthcare needs, the company has robust research and development capabilities and utilizes advanced manufacturing processes. Their flagship product, Pemetrexed Disodium for Injection, has garnered regulatory approvals in key markets including China, the UK, Germany, and Finland. This medication is particularly acclaimed for its effectiveness in treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

The agreement stipulates that Hupan Pharmaceutical, a subsidiary of Lakeside, will be responsible for distributing Huiyu's products to a wide array of hospitals and healthcare institutions. This strategic alignment underscores Lakeside's commitment to enhancing pharmaceutical logistics and distribution capabilities especially within the Asia-Pacific region. Lan Su, the Chief Operating Officer of Lakeside, expressed enthusiasm for the partnership, stating, "Our collaboration with Huiyu Pharmaceutical represents an invaluable opportunity to extend the reach of their innovative oncology solutions and deliver life-saving treatments to patients more efficiently."

Zhao Ding, the President of Huiyu Pharmaceutical, echoed these sentiments, adding, "By partnering with Hupan Pharmaceutical, we aim to facilitate more reliable and efficient distribution channels for our therapies, ensuring that patients have access to essential treatments."

Lakeside Holding, through its subsidiaries—American Bear Logistics and Hupan Pharmaceutical—focuses on providing tailored logistics solutions that encompass both general and specialized sectors. With strategic hubs in major U.S. cities such as Chicago, Dallas, Los Angeles, and New York, American Bear Logistics connects Asia-based logistics service providers with e-commerce platforms in the U.S. The recent acquisition of Hupan Pharmaceutical further positions Lakeside for enhanced service provision within China's healthcare landscape.

The strategic partnership comes at a crucial time as the demand for innovative healthcare solutions continues to rise globally. By leveraging their combined strengths, Lakeside and Huiyu aim to address critical gaps in oncology treatment accessibility, leading to improved patient outcomes and better health management overall.

In conclusion, this partnership not only aims to cater to the immediate healthcare distribution needs but also reflects the growing trend of cross-border collaboration in addressing global health challenges. For more information on this developing story, interested parties can refer to Lakeside's official website.

Safe Harbor Statement: This article contains forward-looking statements regarding Lakeside Holding and Huiyu Pharmaceutical. Actual results may differ from those anticipated due to various risks and uncertainties associated with market dynamics and regulatory developments. Investors are encouraged to consider these factors carefully.

For any media inquiries, please contact Matthew Abenante at [email protected]